MedPage Today on MSN
Ulcerative Colitis: Next Target for CAR T-Cell Therapy?
The range of autoimmune diseases treatable with chimeric antigen receptor (CAR) T-cell therapy could be much broader than ...
1don MSN
Genetic screening technique could enhance CAR-T therapies for multiple myeloma and other cancers
Researchers from Mass General Brigham and the Broad Institute of MIT and Harvard have identified genetic modifications that ...
CAR T cells are patient-derived, genetically engineered immune cells. They are "living drugs" and constitute a milestone in ...
New research has identified genetic modifications that may increase the effectiveness of immunotherapy for multiple myeloma, ...
A team led by scientists at Harvard Medical School, Massachusetts General Hospital, and the Broad Institute of MIT and ...
Researchers found that zeaxanthin, long associated with eye health, may also boost the body’s immune response against cancer.
Researchers from Mass General Brigham and the Broad Institute of MIT and Harvard have identified genetic modifications that can improve the efficacy ...
News-Medical.Net on MSN
Genetic modification enhances "living drugs" for blood cancers
CAR T cells are patient-derived, genetically engineered immune cells. They are "living drugs" and constitute a milestone in modern medicine. Equipping T cells, a key cell type of the immune system, ...
Approximately 60% to 70% of patients aged 18 to 65 years will achieve a complete remission, but just 30.5% of these patients ...
Taste receptors are specialized proteins that facilitate the sense of taste. There are different groups of receptors for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback